Abbott Laboratories stock completes $21 billion Exact Sciences acquisition, eyes diagnostics growth amid share dip

Abbott Laboratories (ISIN: US0028241000) has finalized its $21 billion purchase of Exact Sciences, bolstering its cancer diagnostics portfolio. The deal, closed on March 23, 2026, adds $3 billion in projected 2026 revenue but pressures short-term EPS. US investors eye the NYSE-traded ABT stock near its 52-week low of $105.27 USD as a potential value play.

Abbott Laboratories has completed its transformative $21 billion acquisition of Exact Sciences, marking a pivotal expansion into multi-cancer early detection diagnostics. The deal closed on March 23, 2026, after securing all regulatory approvals and shareholder votes, with Exact Sciences delisted from Nasdaq the prior week. This move accelerates Abbott's growth in high-margin diagnostics, projecting $3 billion in additional 2026 sales despite a $0.20 EPS dilution. For US investors, the Abbott Laboratories stock on the NYSE dipped to a 52-week low near $105.27 USD, presenting a potential entry amid reaffirmed full-year guidance.

As of: 24.03.2026

By Dr. Elena Voss, Senior Healthcare Equity Analyst – Abbott Laboratories stock stands at a crossroads post-acquisition, blending oncology innovation with integration risks in a maturing diagnostics market.

Acquisition Details and Strategic Rationale

Abbott Laboratories announced the completion of its $21 billion cash acquisition of Exact Sciences on March 23, 2026. The transaction positions Exact Sciences as a wholly owned subsidiary, integrating its Cologuard and other multi-cancer screening technologies into Abbott's diagnostics division. Management emphasized the strategic fit, noting Exact Sciences' established Medicare coverage for tests as a key enabler for scalable revenue.

The deal priced Exact Sciences shares at $105 each, a premium that drove a 130% surge in its stock over the past year. Abbott funded the purchase through a mix of cash reserves and debt, maintaining a solid current ratio of 1.58 and quick ratio of 1.18. This liquidity supports seamless integration without immediate balance sheet strain.

For US investors, this acquisition diversifies Abbott beyond its core diabetes care and cardiovascular devices. Exact Sciences brings recurring revenue from screening tests, aligning with rising demand for preventive oncology solutions amid aging demographics.

Immediate Market Reaction and Stock Performance

On the New York Stock Exchange, Abbott Laboratories stock opened at $105.58 USD on March 23, 2026, down approximately 1.5% amid broader market pressures and acquisition digestion. The shares hit a 52-week low of $105.24 USD to $105.27 USD, reflecting investor caution over integration costs and EPS dilution.

Despite the dip, institutional interest persists. TABR Capital Management initiated a $7.36 million position with 58,747 shares, representing 2.9% of its portfolio. MP 63 Fund added 300 shares, boosting its stake by 2.29% to $1.72 million. These moves signal confidence in long-term value.

Analysts maintain a Moderate Buy consensus, with an average price target of $136.16 USD, implying over 25% upside from current NYSE levels. Firms like UBS and Benchmark reiterated Buy ratings, citing growth in structural heart and FreeStyle Libre diabetes tech.

Financial Guidance and 2026 Outlook

Abbott reaffirmed its full-year 2026 guidance post-acquisition: adjusted diluted EPS of $5.55 to $5.80 USD and organic sales growth of 6.5% to 7.5%. Q1 2026 EPS is guided at $1.12 to $1.18 USD, absorbing the $0.20 dilution from the deal. This compares favorably to consensus estimates near $5.14 EPS.

Recent quarterly results showed $1.50 EPS on $11.46 billion revenue, up 4.4% year-over-year, with a net margin of 14.72% and return on equity of 17.73%. The acquisition adds high-margin diagnostics, expected to boost top-line growth by 0.5 percentage points in 2026.

Abbott's dividend remains attractive, with a $0.63 quarterly payout declared, annualizing to $2.52 USD and yielding about 2.4% at recent NYSE prices. The payout ratio of 67.74% supports sustainability, marking 56 consecutive years of increases.

Why US Investors Should Watch Closely

US investors hold particular relevance here, as Abbott's NYSE-listed shares (ABT) trade in a liquid market with heavy institutional ownership at 75.18%. The Exact Sciences integration taps into domestic demand for cancer screening, bolstered by recent Medicare legislation for multi-cancer early detection tests.

Pharma and diagnostics firms like Abbott benefit from US healthcare spending trends, projected to grow amid preventive care mandates. For German-speaking investors in Germany, Austria, and Switzerland, ABT offers US market exposure via accessible brokers, with currency-hedged ETFs available.

The stock's forward P/E below historical averages, combined with a beta of 0.74, appeals to defensive portfolios seeking healthcare stability. Insider ownership at 0.46% and low debt-to-equity of 0.19 underscore balance sheet strength.

Synergies and Growth Catalysts in Diagnostics

The acquisition unlocks R&D and manufacturing synergies, with Abbott targeting cost savings to offset dilution within 18 months. Exact Sciences' $3.25 billion trailing revenue and path to profitability enhance Abbott's diagnostics segment, already strong in point-of-care testing.

Key catalysts include upcoming CHAMPION trial readouts for structural heart devices and FreeDM trial success in Type 2 diabetes management via FreeStyle Libre. These validate Abbott's innovation pipeline, critical in a sector facing reimbursement pressures.

Medical technology pricing has stabilized after COVID-era inflation, per Raymond James, supporting margins. Abbott's global footprint, with diversified revenue, mitigates US-specific policy risks.

Risks and Integration Challenges

Short-term risks include integration hurdles, with potential execution delays in merging operations. The $0.20 EPS dilution could weigh on sentiment if synergies lag. Broader sector headwinds like flat pricing and regulatory scrutiny on diagnostics reimbursement persist.

Insider sales totaled 3,055 shares worth $353,097 in recent months, though ownership remains low. Analyst adjustments, such as Daiwa's target cut to $113 USD and Argus to $140 USD, reflect caution. Market volatility around the 52-week low tests resolve.

Macro factors, including interest rates and healthcare policy shifts under new administrations, could impact growth. Abbott's low beta offers some protection, but US investors should monitor Q1 results for integration progress.

Analyst Views and Valuation Perspective

Consensus leans positive, with two Strong Buy and fifteen Buy ratings against four Holds. Targets range from $113 USD to $158 USD, averaging $132.64 to $136.16 USD. Evercore's $138 USD and Freedom Capital's Strong Buy highlight upside.

At a P/E of 28.38 and PEG of 1.68, valuation appears reasonable for a growth healthcare name. Market cap stands at $183.88 billion, with institutional flows supportive. For value hunters, the post-deal dip near NYSE lows merits attention.

US investors benefit from Abbott's track record of resilience, with diagnostics now supercharged for mid-teens EPS growth. German-speaking audiences can access via international platforms, watching for accretion in 2027.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.